Background: Rare germline mutations in DNA repair genes are associated with prostate cancer (PCa) predisposition and prognosis. Objective: To quantify the frequency of germline DNA repair gene mutations in UK PCa cases and controls, in order to more comprehensively evaluate the contribution of individual genes to overall PCa risk and likelihood of aggressive disease. Design, setting, and participants: We sequenced 167 DNA repair and eight PCa candidate genes in a UK-based cohort of 1281 young-onset PCa cases (diagnosed at 60 yr) and 1160 selected controls. Outcome measurements and statistical analysis: Gene-level SKAT-O and gene-set adaptive combination of p values (ADA) analyses were performed separately for cases versus controls, and aggressive (Gleason score !8, n = 201) versus nonaggressive (Gleason score 7, n = 1048) cases. Results and limitations: We identified 233 unique protein truncating variants (PTVs) with minor allele frequency <0.5% in controls in 97 genes. The total proportion of PTV carriers was higher in cases than in controls (15% vs 12%, odds ratio 
Introduction
Prostate cancer (PCa) is the most common solid tumour in men living in the developed world besides nonmelanoma skin cancer and responsible for over 300 000 deaths per year worldwide [1] , although the majority of PCa cases are diagnosed with low-or intermediate-risk disease. Family history (FH) is a strong risk factor for PCa, and twin studies demonstrate a large contribution by heritable genetic factors [2] . Increasing evidence indicates that both common and rare germline variation contribute to PCa predisposition [3, 4] . Rare loss of function (LoF) germline mutations in BRCA2 have convincingly been implicated as contributing to both FH of PCa and increased likelihood of aggressive disease with poor prognosis, whilst lower mutational frequencies or less consistent evidence has also been presented for a small subset of additional DNA repair genes including ATM, BRCA1, BRIP1, CHEK2, GEN1, MSH2, NBN, PALB2 and RAD51D[ 4 _ T D $ D I F F ] [5] [6] [7] .
In this study, we performed screening of 167 genes from DNA damage response and repair pathways within a large UK-based case-control cohort with long follow-up, to further investigate the role of germline DNA repair gene mutations in PCa predisposition, clinical outcome, and survival. To maximise the power in this study, we utilised young-onset cases (diagnosed at 60 yr) and control samples screened for either no PCa FH or low prostatespecific antigen (PSA; <0.5 ng/ml). These results should help inform the composition of future gene panels for clinical screening and risk profiling.
2.
Patients and methods
Study population
Self-reported European ancestry PCa cases were randomly selected from the young-onset (diagnosed at 60 yr) subcohort of the UK Genetic Prostate Cancer Study (UKGPCS) [8] . Control men with no FH of PCa were recruited from GP practices participating in UKGPCS, or those with PSA <0.5 ng/ml were recruited from the Prostate Testing for Cancer and Treatment (ProtecT) trial [9] . Cases and controls were matched for although the age profiles of the case cohort and control men with known age at recruitment were broadly similar (Table 1 ). All studies were approved by the appropriate ethics committees (UKGPCS 848). All participants gave written informed consent.
Analyses were performed comparing all post-quality control (QC)
PCa cases (n = 1281) versus controls (n = 1160), and for case-case comparisons of aggressive (Gleason score !8, n = 201) versus nonaggressive (Gleason score 7, n = 1048) cases (Table 1) .
Target genes
We 
DNA repair pathways, 60 DNA damage response and cell cycle regulation genes, and eight other candidate PCa predisposition genes (HOXB13, MSR1, RNASEL, AR, ESR1, ESR2, NKX3-1, and SPOP; 
Sequence data analysis, variant annotation, and QC
Raw sequencing reads were aligned to GRCh37 using BWA 0.5.8 [10] . Samples reaching !80% of the target at !10Â read depth as defined by Picard v.1.52 (http://broadinstitute.github.io/picard/) and contamination <3% as estimated by verifyBamID v1.1.1 (https://github.com/statgen/ verifyBamID/releases) were genotyped using GATK v2.8-1 [11] . Per-gene coverage levels were assessed using the GATK tool "DiagnoseTargets", with a per-base coverage QC threshold set at !8 reads at base quality !20. Lowquality genotypes were removed according to established thresholds (Supplementary material, Methods) [12] [13] [14] . Standard QC procedures were applied to remove poorly performing samples and variants [15] . These include variant-level filters such as heterozygosity and Supplementary Fig. 3) , and sample-level filters including relatedness and divergent ancestry (Supplementary material, Methods).
Owing to the targeted nature of the sequencing data, ancestry QC was augmented with additional QC data from the OncoArray platform [16] .
Variants were annotated by wANNOVAR [17] To identify associated genes (test 1) we used SKAT-O, a unified test able to tolerate the inclusion of neutral variants or variants with opposing direction of effect, which finds the optimal combination between burden and kernel tests for the tested data [21] . threshold for the tested data set, removing neutral variants and identifying the likely underlying variant-level components of the gene-level signal [22] . Gene-level ADA for genes identified by SKAT-O was run using all tier 1 and 2 variants within these genes and default settings (corresponding to p value truncation thresholds of 0.1-0.2 considered in 0.01 increments) except for increasing to 10 000
permutations and using the mid p value setting [23] .
We subsequently performed an additional gene discovery analysis (test 2) in which ADA was used to identify a candidate gene set rather 
Results

Sequencing and sample summary
After QC, variant data were available for 1281 PCa cases and 1160 control samples. Of 175 genes targeted, three (GTF2H2, PCa = prostate cancer.
SLX1A, and SLX1B) were excluded due to low coverage resulting from segmental duplication and one (PRKDC) was removed as wANNOVAR was unable to annotate coding consequences due to an incomplete RefSeq gene definition (Supplementary Fig. [ 4 To further investigate these SKAT-O association signals, we used ADA to interrogate the combination of variants contributing to the association (HOXB13 and POLL were also included due to the well-characterised role of HOXB13 in PCa predisposition). For both NBN and HOXB13, ADA identified a single-recurrent heterozygous nonsynonymous variant enriched among PCa cases to be responsible for the gene-level signal, whilst for POLL, four of the 15 tested variants were identified to be responsible for potentially modulating risk (three protective and one pathogenic). For XPC, ADA selected six singleton heterozygous variants from the nine variants tested as contributing to the aggressive phenotype, all of which were observed in different individuals (Table 3) .
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Candidate gene-set discovery Fig. 2B ). Three of these genes overlap with the case/control gene set (BRCA2, CHEK2, and MSH2), whilst ERCC2 is unique to the aggressive set. In contrast to other CHEK2 PTVs, the CHEK2 1100delC variant was not enriched among aggressive cases. The combined set of 21 genes identified in these analyses demonstrated a continuum of aggressive phenotype risk ( Supplementary Fig. 7) , with the upper tail defining predisposition genes with a lower risk of aggressive disease 2 0 1 9 ) 3 2 9 -3 3 7 and the lower tail the converse. We partitioned the gene set into nonoverlapping sets of 18 genes in the predisposition panel (Predis18) and four in the aggressive panel (Agg4), with CHEK2 split (1100delC in Predis18 and other PTVs in Agg4; Fig. 2C ). As would be expected, given the phenotype criteria, Agg4 carriers showed significant enrichment for several clinical indicators of aggressive disease (higher PSA, Gleason score, tumour stage, and nodal spread). Predis18 carriers showed no association with any clinical variable (Table 4) . A modest increase in PCa FH rate was observed among Predis18 carriers compared with noncarriers, whilst PCa FH rates were lower among Agg4 carriers; however, both these trends were nonsignificant. Suggestive but nonsignificant increases in rates of breast and pancreatic cancer FH were also observed for carriers of the Agg4 gene set (Supplementary Table 5 ). Kaplan-Meier survival analysis showed a significant global difference across gene-set carriers (Agg4, Predis18, and noncarriers) for both all-cause and PCa-specific mortality (log-rank test, p all-cause = 9.8 Â 10
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). This is attributable to Agg4 carriers demonstrating significantly worse survival than noncarriers, as survival between Predis18 carriers and [ ( F i g . _ 2 ) T D $ F I G ] noncarriers was very similar. For all-cause survival (Fig. 3A) , 5-yr survival rates were 60% for Agg4 (95% CI 34-79%), 93% for Predis18 (95% CI 85-97%), and 89% for noncarriers (95% CI 87-91%). The hazard ratio for Agg4 carriers compared with noncarriers was 2.69 (95% CI 1.32-5.50; Fig. 3C ). A similar pattern was observed when considering only PCaspecific survival (Fig. 3B) , though hazard ratios were not statistically significant, possibly due to the reduction in the number of events (282 compared with 212). Five-year survival rates were 60% for Agg4 (95% CI 34-79%), 94% for Predis18 (95% CI 86-98%), and 91% for noncarriers (95% CI 89-92%). The hazard ratio for Agg4 carriers compared with noncarriers was 1.83 (95% CI 0.77-4.39; Fig. 3D ).
Discussion
Direct sequencing approaches are required to investigate the effect of rarer germline variants in complex disease predisposition; however, to date, these studies in PCa have generally been smaller in size, considered only a handful of candidate genes, or lacked control cohorts. In this study, we investigated the role of DNA repair and damage response genes in predisposition to PCa and aggressive disease in a case/control cohort. We focused on protein truncating (tier 1) and predicted conserved (tier 2) variants using both gene-level SKAT-O and gene-set-level ADA analyses. Gene-level analysis of tier 1 and 2 variants identified significant associations in NBN for PCa predisposition and XPC for disease aggressiveness. The NBN signal was refined by ADA to rs61753720, a G>T single nucleotide variant (SNV) resulting in a D95N substitution. A previous study by the ICPCG consortium found this variant at a low frequency in both unselected (1/613) and familial (1/121) Finnish PCa cohorts, and absent (0/440) in controls [26] . For the association between the XPC gene and a higher Gleason score, ADA selected multiple singleton SNVs across the gene. Both POLL and HOXB13 were also marginally associated with PCa predisposition in the case/control analysis. Since the role of HOXB13 rs138213197 in PCa risk has been well established, sample size may have been a limiting factor in achieving Bonferroni-corrected significance, suggesting that POLL may also warrant additional follow-up in larger cohorts or meta-analyses of individual studies.
Gene-set-level analysis identified 20 genes in which PTVs were associated with PCa predisposition. These included the established BRCA1/2 genes, a handful of additional genes that have been indicated previously as prospective PCa candidates (ATM, CHEK2, GEN1, MSH2, and RNASEL), and several novel genes for which limited substantive evidence for a role in PCa predisposition has been presented to date (BLM, CDC25C, ERCC3, LIG4, MSH5, NEIL2, NHEJ1, PARP2, POLD1, POLE, POLM, RECQL4, and TDP1).
We furthermore identified four genes associated with more aggressive PCa phenotype, three of which overlapped the 20-gene PCa predisposition set. These include BRCA2, for which association with a more aggressive phenotype has reliably been demonstrated [6, 7, 27, 28] , whilst we also present evidence that carriers of PTVs in MSH2, CHEK2 (excluding 1100delC), and ERCC2 also have a substantially higher likelihood of developing aggressive disease. Our criteria to stratify cases for the aggressive phenotype analysis (Gleason score 7 vs !8) were chosen to maximise the homogeneity and risk of the aggressive group. Within the Gleason 7 category, however, Gleason 4 + 3 patients have poorer prognosis than Gleason 3 + 4 patients, with these two subgroups categorised separately according to the prognostic grade grouping method [29] . We therefore set, we nevertheless observed substantial enrichment over noncarriers for nodal invasion (38% vs 9.5%), metastatic disease (18% vs 11%), and reduced survival (PCa-specific 5-yr survival rate 60% vs 91%), suggesting that these genes could potentially demonstrate clinical utility for the identification of individuals at a higher risk of advanced disease prior to progression. The absence of BRCA1 and ATM from our aggressive gene set is however notable, as PTVs in these genes have been implicated in increased risks of metastatic and lethal PCa cancer previously [6, 7, 30] . This discrepancy may in part reflect our use of Gleason score to define aggressive disease due to the modest proportion of patients with metastatic disease in our unselected cohort (7.2% of overall cohort,11% excluding unknown status) in comparison with the more stringent metastatic or lethality indicators employed elsewhere in cohorts enriched for these outcomes, or alternatively that these genes confer lower influence upon aggressiveness in younger patients. It is also noteworthy that whilst CHEK2 was associated with PCa predisposition for both 1100delC and other PTVs, only the non-1100delC CHEK2 variants were found to contribute towards aggressive disease in our study. This observation, however, contrasts with a recent report in which only the 1100delC variant and not overall CHEK2 mutations were enriched in lethal PCa patients [31] , and therefore requires further validation in independent cohorts. These combined reports could, however, potentially indicate that the downstream functional consequence of the 1100delC founder mutation may partly differ from those of other CHEK2 PTVs in prostate tissue.
Whilst the novel genes that we have identified represent exciting candidate moderate-penetrance PCa-risk genes, these findings nonetheless require additional validation in independent cohorts. In particular, we note that the optimal p value truncation thresholds used by ADA are tuned towards greater sensitivity than specificity to maximise power for rare variant discovery in sequencing study sample sizes, and no suitable replication set was available for confirmation of our findings. Furthermore, even though this is the largest DNA repair gene germline sequencing study for PCa to date, our power to detect rare associations with moderate effect sizes remained modest.
Whilst our strategy of using screened controls (no PCa FH or PSA <0.5 ng/ml) potentially increased our power to detect associations, this also has the potential to introduce bias in our case/control analyses. We therefore cannot completely exclude the possibility that the use of PSA or FH in our control selection criteria led to an observed depletion of LoF variants among controls; although this would imply a uniform direction and comparatively high penetrance of effects across a wide range of DNA repair genes and pathways 
Conclusions
In this study, we confirmed previous PCa predisposition gene reports and also present evidence for additional novel genes. Our combined gene and gene-set-level analyses provide evidence for a prospective screening panel of 23 genes that may facilitate identification of individuals at a higher PCa risk prior to disease onset, who would warrant enhanced screening. In addition, PCa patients who are carriers of mutations in these genes could potentially benefit from personalised treatment pathways [27, 32] . We believe that these genes warrant evaluation by the wider scientific and clinical communities in larger prospective studies or meta-analyses. There is also a need to formally test the ability of these genes to predict survival in an independent cohort within aggressiveness strata.
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